Coherus Management to Participate in the 2024 Citi Global Healthcare Conference
Coherus BioSciences (NASDAQ: CHRS) announced its participation in the 2024 Citi Global Healthcare Conference. Dr. Theresa LaVallee, Chief Development Officer, will be a panelist on the Novel Mechanisms in Oncology Panel scheduled for December 3, 2024, at 3:15 p.m. ET. The panel discussion will be available via webcast through the Investor Events and Presentations section of the Coherus website.
Coherus BioSciences (NASDAQ: CHRS) ha annunciato la sua partecipazione alla Conferenza Sanitaria Globale Citi 2024. La Dr.ssa Theresa LaVallee, Responsabile dello Sviluppo, sarà relatrice al Panel sui Nuovi Meccanismi in Oncologia previsto per il 3 dicembre 2024, alle 15:15 ET. La discussione del panel sarà disponibile in webcast nella sezione Eventi per Investitori e Presentazioni del sito web di Coherus.
Coherus BioSciences (NASDAQ: CHRS) anunció su participación en la Conferencia Global de Salud Citi 2024. La Dra. Theresa LaVallee, Directora de Desarrollo, será panelista en el Panel de Nuevos Mecanismos en Oncología programado para el 3 de diciembre de 2024, a las 3:15 p.m. ET. La discusión del panel estará disponible a través de una transmisión en vivo en la sección de Eventos para Inversores y Presentaciones en el sitio web de Coherus.
Coherus BioSciences (NASDAQ: CHRS)는 2024 Citi 글로벌 헬스케어 컨퍼런스에 참가한다고 발표했습니다. 개발 책임자인 테레사 라발리 박사는 2024년 12월 3일 오후 3시 15분 ET에 예정된 종양학의 새로운 메커니즘 패널에서 패널리스트로 참여할 예정입니다. 패널 토론은 Coherus 웹사이트의 투자자 이벤트 및 발표 섹션을 통해 웹캐스트로 제공될 예정입니다.
Coherus BioSciences (NASDAQ: CHRS) a annoncé sa participation à la Conférence Mondiale de la Santé Citi 2024. Dr. Theresa LaVallee, Directrice du Développement, sera panéliste lors du Panneau sur les Nouveaux Mécanismes en Oncologie prévu pour le 3 décembre 2024 à 15h15 ET. La discussion du panel sera disponible en webcast dans la section Événements pour Investisseurs et Présentations sur le site web de Coherus.
Coherus BioSciences (NASDAQ: CHRS) gab seine Teilnahme an der 2024 Citi Global Healthcare Conference bekannt. Dr. Theresa LaVallee, Chief Development Officer, wird als Panelistin am Panel über Neuen Mechanismen in der Onkologie teilnehmen, das für den 3. Dezember 2024 um 15:15 Uhr ET geplant ist. Die Podiumsdiskussion wird über einen Webcast in der Rubrik Investorenveranstaltungen und Präsentationen auf der Website von Coherus verfügbar sein.
- None.
- None.
REDWOOD CITY, Calif., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus,” NASDAQ: CHRS) today announced that senior management will participate in the 2024 Citi Global Healthcare Conference, with Dr. Theresa LaVallee, Chief Development Officer, sitting on the Novel Mechanisms in Oncology Panel on December 3, 2024, at 3:15 p.m. ET.
The panel discussion will be accessible via webcast through a link on the Investor Events and Presentations section of the Coherus website: https://investors.coherus.com/events-presentations.
Coherus Contact Information:
For Investors:
Jodi Sievers
VP, Investor Relations & Corporate Communications
IR@coherus.com
FAQ
When is Coherus (CHRS) participating in the 2024 Citi Global Healthcare Conference?
Who will represent Coherus (CHRS) at the 2024 Citi Healthcare Conference?
How can investors access the Coherus (CHRS) panel discussion at the Citi Healthcare Conference?
What panel will Coherus (CHRS) participate in at the 2024 Citi Healthcare Conference?
